NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase I Norovirus Challenge Model

Phase 1

Completed

Conditions: Gastroenteritis Norovirus

Interventions: Biological: Norovirus GII.4 Challenge Pool

First Posted Date: 2019-11-22

Last Posted Date: 2024-11-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT04174560

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati, Ohio, United States

Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Truvada Tablet
Drug: Dapivirine (DPV) Vaginal Ring (VR)-004

First Posted Date: 2019-10-25

Last Posted Date: 2023-08-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 394

Registration Number: NCT04140266

Locations: 🇺🇬
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda
🇲🇼
Blantyre CRS (Johns Hopkins Research Project/College of Medicine), Blantyre, Malawi
🇿🇼
Zengeza CRS, Chitungwiza, Mashonaland East, Zimbabwe

and more 1 locations

Mepolizumab in Episodic Angioedema With Eosinophilia

Phase 2

Terminated

Conditions: Eosinophilia
Angioedema

Interventions: Biological: mepolizumab

First Posted Date: 2019-10-16

Last Posted Date: 2024-04-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 5

Registration Number: NCT04128371

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety and Pharmacokinetics of Rezafungin

Phase 1

Terminated

Conditions: Fungal Infection

Interventions: Other: Placebo
Drug: Rezafungin

First Posted Date: 2019-10-07

Last Posted Date: 2021-07-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 14

Registration Number: NCT04117607

Locations: 🇺🇸
ICON Early Phase Services Clinical Research Unit, San Antonio, Texas, United States

Malaria Prevalence Around Maferinyah, Guinea

Completed

Conditions: Malaria

First Posted Date: 2019-09-26

Last Posted Date: 2023-11-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 3392

Registration Number: NCT04105855

Locations: 🇬🇳
Maferinyah Rural Health Training and Research Center, Maferinyah, Guinea

Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)

Phase 1

Recruiting

Conditions: Idiopathic CD4 Lymphopenia

Interventions: Biological: Belimumab

First Posted Date: 2019-09-20

Last Posted Date: 2024-12-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT04097561

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Treg Modulation With CD28 and IL-6 Receptor Antagonists

Phase 1

Completed

Conditions: Living-Donor Kidney Transplant
Kidney Transplant Recipients

Interventions: Biological: lulizumab pegol
Biological: antithymocyte globulin (rabbit)
Drug: methylprednisolone
Biological: tocilizumab
Drug: Prednisone
Drug: everolimus
Biological: belatacept
Drug: mycophenolate mofetil
Drug: mycophenolic acid

First Posted Date: 2019-08-26

Last Posted Date: 2024-10-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT04066114

Locations: 🇺🇸
Cleveland Clinic Foundation: Transplantation, Cleveland, Ohio, United States
🇺🇸
University of California San Francisco School of Medicine: Transplantation, San Francisco, California, United States
🇺🇸
University of Alabama School of Medicine: Transplantation, Birmingham, Alabama, United States

and more 4 locations

Paradoxical Tuberculosis Reactions in Patients Without HIV Infection

Recruiting

Conditions: Tuberculosis

First Posted Date: 2019-08-09

Last Posted Date: 2024-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 70

Registration Number: NCT04052022

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Phase 3

Recruiting

Conditions: Secondary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Biological: Best Available Therapy (BAT)

First Posted Date: 2019-08-07

Last Posted Date: 2024-12-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 156

Registration Number: NCT04047628

Locations: 🇺🇸
Maxine Mesigner Multiple Sclerosis Comprehensive Care Center, Baylor College of Medicine Medical Center, Houston, Texas, United States
🇺🇸
Virginia Commonwealth University Multiple Sclerosis Treatment and Research Center, Richmond, Virginia, United States
🇺🇸
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 17 locations

Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy

Phase 1

Withdrawn

Conditions: Hepatitis B Virus

Interventions: Biological: Cemiplimab

First Posted Date: 2019-08-06

Last Posted Date: 2023-09-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT04046107

Locations: 🇨🇦
Toronto General Hospital CRS, Toronto, Ontario, Canada
🇺🇸
Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States
🇧🇷
12201, Hospital Nossa Senhora da Conceicao CRS, Porto Alegre, Brazil

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy